Follow The Filings

ASMB Assembly Biosciences Inc.

Health Care, filed as ASSEMBLY BIOSCIENCES INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.2%
  • $44M
  • 1 add

In 2026 Q2 Farallon Capital Management added to Assembly Biosciences.

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Add 0.20%

Who owns ASMB

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management 0.20%, was 0.19% Add +30.7% 1,604,590 $44M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ASMB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ASMB insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 11 stock grants and 5 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K/A 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 12 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — — $72.3M
Net income -$61.23M -$40.18M -$6.12M
Net margin * — — -8.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $133.79M $115.5M $254.55M
Total non-current assets * $3.04M $3.66M $3.04M
Total assets $136.82M $119.17M $257.59M
Total current liabilities $39.22M $47.8M $48.78M
Total non-current liabilities * $56.5M $38.01M $2.06M
Total equity $41.1M $33.36M $206.75M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $22.74M -$51.12M -$41.09M
Cash from investing -$69.14M $40.17M -$113.47M
Cash from financing $13.82M $29.45M $174.67M
Net change in cash -$32.58M $18.5M $20.11M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.